Shiven Patel, MD, MBA, FACP
Shiven B. Patel, MD, MBA, FACP, is an Associate Professor in the Division of Oncology, Department of Medicine, at the University of Utah, School of Medicine, and an Investigator at the Huntsman Cancer Institute. Dr. Patel is a specialist in adult hematology and medical oncology, and his main areas of interest include thoracic (head & neck, thyroid, lung, mesothelioma and thymic cancers).
Dr. Patel earned his bachelor’s and medical degrees from The University of Florida in Gainesville, Florida. He then went on to complete an Internal Medicine residency at the University of Maryland School Of Medicine in Baltimore, Maryland. Next he served as an attending physician in Hospitalist Medicine at MedStar Franklin Square in Rosedale, Maryland. Dr. Patel then completed a combined fellowship in hematology and oncology at the University of Utah and the Huntsman Cancer Institute. He served as the Chief Fellow his final year of training and sat on the Graduate Medical Education committee at the University of Utah. Most recently, he completed the MBA program at Indiana University, Kelley School of Business in Indianapolis, Indiana, as well as the Lean Six Sigma Green Belt Certification, through Professional Education at the University of Utah in Salt Lake City.
Dr. Patel is board certified in internal medicine, hematology, and oncology. He is a member of several national organizations such as the American Society of Clinical Oncology, American Society of Hematology and American Association of Cancer Research.
Throughout his medical training, Dr. Patel has been involved in both laboratory and clinical research. He has presented his work at multiple national meetings and published these findings in peer-review articles. He is a co-investigator in a number of clinical trials at the Huntsman Cancer Institute and is working to bring more studies of all phases to benefit his patients to the Huntsman Cancer Institute.
Financial relationships
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:TakedaTopic:Speaker/Consultant/Ad BoardDate added:12/04/2023Date updated:12/04/2023Relationship end date:03/25/2022
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:RegeneronTopic:Speaker/Consultant/Ad BoardDate added:12/04/2023Date updated:12/04/2023Relationship end date:06/22/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:MerckTopic:Speaker/Consultant/Ad BoardDate added:12/04/2023Date updated:12/04/2023Relationship end date:03/30/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:AstraZenecaTopic:Speaker/Consultant/Ad BoardDate added:12/04/2023Date updated:12/04/2023Relationship end date:06/23/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:BMSTopic:Speaker/Consultant/Ad BoardDate added:12/04/2023Date updated:12/04/2023Relationship end date:07/20/2023
-
Attribution:SelfType of financial relationship:Professional ServicesIneligible company:PfizerTopic:Speaker/Consultant/Ad BoardDate added:12/04/2023Date updated:12/04/2023Relationship end date:11/02/2023